The Ambitious Work Programme of the European Commission
This article was originally published in SRA
Executive Summary
Someone has at last come out and said it - the revision of the European Union's (EU) Medical Devices Directive (MDD; Directive 93/42/EEC) that is underway has been far from the simple process it was meant to be. Speaking at a recent industry conference, Mike Kreuzer of the UK Association of British Healthcare Industries (ABHI) said: “All the way along the line people have said [it] was routine and straightforward. It has in fact been extremely complicated, it remains complicated and it remains in fact potentially quite dangerous for this industry.”
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.